Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 in HER2-positive gastric or GEJ adenocarcinoma
NCT07152405Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BL-M07D1 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Biokin Pharmaceutical. Primary endpoints: Overall Survival at 24 months and Progression-Free Survival at 24 months. Started Sep 2025; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07152405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152405.